Literature DB >> 10509818

Characterization of neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and their fragments.

G Küttner1, A Kramer, G Schmidtke, E Giessmann, L Dong, D Roggenbuck, C Scholz, M Seifert, R D Stigler, J Schneider-Mergener, T Porstmann, W Höhne.   

Abstract

Single-chain Fv fragments (scFv) were generated from two murine monoclonal antibodies directed to the neutralizing epitopes of the pre-S1 and pre-S2 region of hepatitis B virus, respectively, using different assembly cloning strategies. The scFv fragments were solubly expressed in E. coli. Dissociation constants were in the nanomolar range for all forms (whole IgG antibodies, Fab fragment and scFv fragments). The epitopes of both antibodies were mapped using solid phase peptide synthesis on continuous cellulose membranes and turned out to be linear determinants. The minimal epitope for the anti-pre-S2 antibody 1F6 was identified to be DPRVRGLYF (amino acid 133-141 of the pre-S region). For the anti-pre-S1 antibody MA 18/7 the minimal epitope proved to be the hexamer LDPAFR (amino acid 30-35 of the pre-S region). Complete substitutional analyses as well as truncation experiments revealed key residues for these antibody-antigen interactions. On the basis of those results we used computer-assisted modeling techniques to suggest models for both antibody-peptide interactions providing insight into the structural basis of these molecular recognitions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509818     DOI: 10.1016/s0161-5890(99)00074-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins.

Authors:  Wei-Guo Hu; Jun Wei; Heng-Chuan Xia; Xin-Xiu Yang; Feng Li; Guang-Di Li; Yuan Wang; Zu-Chuan Zhang
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

Review 2.  Applications of human hepatitis B virus preS domain in bio- and nanotechnology.

Authors:  Riki Toita; Takahito Kawano; Jeong-Hun Kang; Masaharu Murata
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

3.  Pre-structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus.

Authors:  Seung-Wook Chi; Do-Hyoung Kim; Si-Hyung Lee; Iksoo Chang; Kyou-Hoon Han
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

4.  A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites.

Authors:  Cheng-Wen Lin; Suh-Chin Wu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.

Authors:  Verena Hehle; Maxime Beretta; Maryline Bourgine; Malika Ait-Goughoulte; Cyril Planchais; Solen Morisse; Benjamin Vesin; Valérie Lorin; Thierry Hieu; Andrea Stauffer; Oriane Fiquet; Jordan D Dimitrov; Marie-Louise Michel; Marie-Noëlle Ungeheuer; Camille Sureau; Stanislas Pol; James P Di Santo; Hélène Strick-Marchand; Nadège Pelletier; Hugo Mouquet
Journal:  J Exp Med       Date:  2020-10-05       Impact factor: 14.307

6.  A 33-residue peptide tag increases solubility and stability of Escherichia coli produced single-chain antibody fragments.

Authors:  Yang Wang; Wenjie Yuan; Siqi Guo; Qiqi Li; Xiaomei Chen; Cheng Li; Qianying Liu; Lei Sun; Zhenguo Chen; Zhenghong Yuan; Cheng Luo; Shijie Chen; Shuping Tong; Michael Nassal; Yu-Mei Wen; Yong-Xiang Wang
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

7.  An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion.

Authors:  Cheng Li; Yang Wang; Tiantian Liu; Matthias Niklasch; Ke Qiao; Sarah Durand; Li Chen; Mifang Liang; Thomas F Baumert; Shuping Tong; Michael Nassal; Yu-Mei Wen; Yong-Xiang Wang
Journal:  Antiviral Res       Date:  2018-12-30       Impact factor: 10.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.